Climb Bio, Inc. (NasdaqGM: CLYM)
Health Care · Biotechnology · US
$16.12
-6.71% today · +596.8% 1Y
Climb Bio, Inc. (NasdaqGM: CLYM) operates in the Biotechnology industry within the Health Care sector. The company is valued at $992.50M and employs 28 people.
Over the last twelve months the share price has gained 596.8%, trading between 1.54 and 18.14.
Tweenvest scores Climb Bio, Inc. across four factors: quality 29/100. Its strongest factor is quality.
CLYM price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $992.50M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -0.83
- Dividend yield
- —
- Beta (5Y)
- 0.08
- 52-week high
- $18.14
- 52-week low
- $1.54
- Avg volume (3M)
- —
- Shares outstanding
- 57.44M
- Employees
- 28
- Next earnings
- —
About Climb Bio, Inc.
Climb Bio, Inc. is a biopharmaceutical firm dedicated to crafting therapeutic solutions for inflammatory diseases driven by autoimmune responses. Its primary investigational asset is budoprutug, an anti-CD19 monoclonal antibody. This treatment is being advanced for a range of autoimmune conditions, including systemic lupus erythematosus, lupus nephritis, immune thrombocytopenia, and membranous nephropathy. The entity, established in 2018, officially rebranded as Climb Bio, Inc. in October 2024, having previously operated under the name Eliem Therapeutics, Inc. Its corporate headquarters are situated in Wilmington, Delaware.
- ISIN
- US28658R1068
- Founded
- 2018
- Listed since
- Aug 10, 2021
- Exchange
- Nasdaq Global Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $261.61 | -1.57% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $442.27 | +0.01% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $148.80 | +0.02% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $550.52 | -0.42% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $823.79 | -1.17% |
| argenx SEENXTBR: ARGX | $64.17B | €897.60 | +2.09% |
| Moderna, Inc.NasdaqGS: MRNA | $63.41B | $146.35 | -7.86% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
Figures last refreshed Aug 18, 2026.